Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis

A single somatic mutation, V617F, in Janus kinase 2 (JAK2) is one of the causes of myeloproliferative neoplasms (MPNs), including primary myelofibrosis, and the JAK2V617F mutant kinase is a therapeutic target in MPN. However, inhibition of wild-type (WT) JAK2 can decrease the erythrocyte or platelet...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakaya, Y, Shide, K, Naito, H, Niwa, T, Horio, T, Miyake, J, Shimoda, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913942/
https://www.ncbi.nlm.nih.gov/pubmed/24413068
http://dx.doi.org/10.1038/bcj.2013.73

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913942/
https://www.ncbi.nlm.nih.gov/pubmed/24413068
http://dx.doi.org/10.1038/bcj.2013.73

Ejemplares similares